BioNotebook: Six deals and a name change; Spectrum/CASI, Five Prime/GSK and more

 
• By Mandy Jackson

CASI will develop Spectrum drugs in China; GlaxoSmithKline options Five Prime candidates; MedGenesis licenses technology to Pfizer; Soon-Shiong's NantBioScience initiates cancer collaboration; ImaginAb expands imaging agent pipeline; Akashi acquires DMD drug; and Oxygen changes name to Tenax.

More from Anticancer

More from Therapy Areas